The difference of the change of finger surface temperature after short time cold stress test between Parkinson disease and Multiple system atrophy
Objective: To examine whether there are differences of the change of finger surface temperature (FST) after short time cold stress test between Parkinson disease (PD),…A clinical and pathological study of small fibers in Friedreich´s Ataxia
Objective: To investigate the small fibers pathology in Friedreich´s Ataxia (FRDA). Background: FRDA is an inherited movement disorder caused by homozygous GAA expansions in the…Gastrointestinal Symptoms and Enteric Nerve Dysfunction in A53T Mice
Objective: To investigate the relationship between α synucleinopathy-induced enteric neuropathy and gastrointestinal dysfunction in A53T mice. Background: Approximately 80-90% of PD patients suffer from GI…Predictors of cognitive impairment in multiple system atrophy
Objective: To determine predictors of cognitive impairment in patients with multiple system atrophy (MSA). Background: Although dementia is not a diagnostic criteria for MSA, an…A registry study of multiple system atrophy in Hokkaido, Japan: HoRC-MSA Project 2014-16
Objective: To investigate the epidemiological aspects of multiple system atrophy (MSA) in Hokkaido, Japan by using the Hokkaido Rare disease Consortium for MSA (HoRC-MSA). Background:…Cardiac Autonomic Dysregulation in Probable Multiple System Atrophy
Objective: The objective was to retrospectively study the nature of cardiac autonomic dysfunction and the effect of phenotype on it in probable Multiple System Atrophy…The diagnostic challenges of patients with possible multiple system atrophy
Objective: The aim of the this study to review the diagnostic challenges of MSA and to evaluate the patients with different clinic types of MSA-…Gastrointestinal transit time in Parkinson’s disease -a novel 3D method
Objective: To study the GI transit time with a novel ambulatory electromagnetic system in PD patients and healthy controls. Background: The majority of Parkinson’s disease…The FDA is listening: Integrating the voice of the patient in drug development for Parkinson’s and Huntington’s diseases.
Objective: To present highlights from the Patient-Focused Drug Development (PFDD) meetings held at FDA for Parkinson’s disease (PD) and Huntington’s disease (HD) to raise awareness…Pancreatic polypeptide plasma levels in Parkinson’s disease – a marker of parasympathetic denervation
Objective: To study plasma PP concentration during sham feeding in PD patients and healthy controls, as a measure of pancreatic vagal innervation. Background: Most patients…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 24
- Next Page »